Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frits van Rhee

Showing results (161-170 of 274) with videos related to

Pageof 28
Sort By:
Journal of Hematology & Oncology|August 9, 2020
The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myelomaSamrat Roy Choudhury, Cody Ashby, Ruslana Tytarenko, et al.
Haematologica|January 11, 2024
Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman diseaseMateo Sarmiento Bustamante, Sheila K Pierson, Yue Ren, et al.
Clinical Hematology International|September 30, 2024
Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple MyelomaTanvi H Patel, Ramya Bachu, Trilok Shrivastava, et al.
Blood Cancer Journal|August 11, 2019
An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q SyndromeJeffrey R Sawyer, Erming Tian, Brian A Walker, et al.
Blood|May 22, 2008
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalitiesBart Barlogie, Mauricio Pineda-Roman, Frits van Rhee, et al.
Blood Advances|November 22, 2021
Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myelomaMeera Mohan, Samantha Kendrick, Aniko Szabo, et al.
Blood Advances|January 9, 2025
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myelomaSamer Al Hadidi, Obada Ababneh, Carolina Schinke, et al.
The Journal of Clinical Investigation|October 26, 2023
BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesionsFumou Sun, Yan Cheng, Jin-Ran Chen, et al.
Haematologica|May 30, 2015
Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)Rashid Khan, Madhav Dhodapkar, Adam Rosenthal, et al.
Blood|September 27, 2007
Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989Bart Barlogie, Guido Tricot, Jeff Haessler, et al.
Pageof 28

Showing results (161-170 of 274) with videos related to

Sort By:
Pageof 28
Journal of Hematology & Oncology|August 9, 2020
The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myelomaSamrat Roy Choudhury, Cody Ashby, Ruslana Tytarenko, et al.
Haematologica|January 11, 2024
Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman diseaseMateo Sarmiento Bustamante, Sheila K Pierson, Yue Ren, et al.
Clinical Hematology International|September 30, 2024
Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple MyelomaTanvi H Patel, Ramya Bachu, Trilok Shrivastava, et al.
Blood Cancer Journal|August 11, 2019
An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q SyndromeJeffrey R Sawyer, Erming Tian, Brian A Walker, et al.
Blood|May 22, 2008
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalitiesBart Barlogie, Mauricio Pineda-Roman, Frits van Rhee, et al.
Blood Advances|November 22, 2021
Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myelomaMeera Mohan, Samantha Kendrick, Aniko Szabo, et al.
Blood Advances|January 9, 2025
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myelomaSamer Al Hadidi, Obada Ababneh, Carolina Schinke, et al.
The Journal of Clinical Investigation|October 26, 2023
BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesionsFumou Sun, Yan Cheng, Jin-Ran Chen, et al.
Haematologica|May 30, 2015
Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)Rashid Khan, Madhav Dhodapkar, Adam Rosenthal, et al.
Blood|September 27, 2007
Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989Bart Barlogie, Guido Tricot, Jeff Haessler, et al.
Pageof 28